CN114072503A - 载脂蛋白b拮抗剂 - Google Patents

载脂蛋白b拮抗剂 Download PDF

Info

Publication number
CN114072503A
CN114072503A CN202080048130.6A CN202080048130A CN114072503A CN 114072503 A CN114072503 A CN 114072503A CN 202080048130 A CN202080048130 A CN 202080048130A CN 114072503 A CN114072503 A CN 114072503A
Authority
CN
China
Prior art keywords
seq
nucleotide sequence
double
sense
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080048130.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·卡恩
D·米切尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argonot Rna Co ltd
Original Assignee
Argonot Rna Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1909500.9A external-priority patent/GB201909500D0/en
Priority claimed from GBGB1910526.1A external-priority patent/GB201910526D0/en
Priority claimed from GBGB2000906.4A external-priority patent/GB202000906D0/en
Application filed by Argonot Rna Co ltd filed Critical Argonot Rna Co ltd
Publication of CN114072503A publication Critical patent/CN114072503A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080048130.6A 2019-07-02 2020-06-30 载脂蛋白b拮抗剂 Pending CN114072503A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1909500.9A GB201909500D0 (en) 2019-07-02 2019-07-02 Antagonist
GB1909500.9 2019-07-02
GBGB1910526.1A GB201910526D0 (en) 2019-07-23 2019-07-23 Antagonist
GB1910526.1 2019-07-23
GB2000906.4 2020-01-22
GBGB2000906.4A GB202000906D0 (en) 2020-01-22 2020-01-22 Antagonist
PCT/GB2020/051573 WO2021001646A2 (en) 2019-07-02 2020-06-30 Apolipoprotein b antagonist

Publications (1)

Publication Number Publication Date
CN114072503A true CN114072503A (zh) 2022-02-18

Family

ID=71949646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080048130.6A Pending CN114072503A (zh) 2019-07-02 2020-06-30 载脂蛋白b拮抗剂

Country Status (7)

Country Link
US (1) US20230027604A1 (https=)
EP (1) EP3965781A2 (https=)
JP (1) JP7463410B2 (https=)
CN (1) CN114072503A (https=)
CA (1) CA3143404C (https=)
GB (1) GB2585278B (https=)
WO (1) WO2021001646A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202020534D0 (en) * 2020-12-23 2021-02-03 Argonaute Rna Ltd Conjugate
US20250304966A1 (en) * 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041508A2 (en) * 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
GB2618915B (en) * 2022-05-18 2024-08-14 Argonaute Rna Ltd Treatment of cardiovascular disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133074A (zh) * 2004-09-24 2008-02-27 阿尔尼拉姆医药品有限公司 APOB的RNAi调节及其用途
WO2009120887A2 (en) * 2008-03-27 2009-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for mediating rnai in vivo
CN107106564A (zh) * 2014-12-26 2017-08-29 日东电工株式会社 用于治疗与kras突变相关的恶性肿瘤的方法和组合物
WO2022136466A1 (en) * 2020-12-23 2022-06-30 Argonaute RNA Limited Treatment of cardiovascular disease
CN116234582A (zh) * 2020-06-24 2023-06-06 萨普雷米科技有限公司 GalNAc和皂苷的缀合物、包含所述缀合物和GalNAc-寡核苷酸缀合物的治疗性组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
US8236943B2 (en) * 2009-07-01 2012-08-07 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
US20150025122A1 (en) * 2009-10-12 2015-01-22 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133074A (zh) * 2004-09-24 2008-02-27 阿尔尼拉姆医药品有限公司 APOB的RNAi调节及其用途
WO2009120887A2 (en) * 2008-03-27 2009-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for mediating rnai in vivo
CN107106564A (zh) * 2014-12-26 2017-08-29 日东电工株式会社 用于治疗与kras突变相关的恶性肿瘤的方法和组合物
CN116234582A (zh) * 2020-06-24 2023-06-06 萨普雷米科技有限公司 GalNAc和皂苷的缀合物、包含所述缀合物和GalNAc-寡核苷酸缀合物的治疗性组合物
WO2022136466A1 (en) * 2020-12-23 2022-06-30 Argonaute RNA Limited Treatment of cardiovascular disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALLISON SJ等: "RNA interference by single- and double-stranded siRNA with a DNA extension containing a 3’ nuclease-resistant mini-hairpin structure", 《MOL THER NUCLEIC ACIDS》, vol. 2, no. 1, 7 January 2014 (2014-01-07), pages 2 *
SHARMA VK等: "Oligonucleotide therapeutics: chemistry, delivery and clinical progress", 《FUTURE MED CHEM》, vol. 7, no. 16, 31 December 2015 (2015-12-31), pages 2221 - 2242, XP055428414, DOI: 10.4155/fmc.15.144 *
SPRINGER AD等: "GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics", 《NUCLEIC ACID THER》, vol. 28, no. 3, 30 June 2018 (2018-06-30), pages 110, XP055555952, DOI: 10.1089/nat.2018.0736 *
张秀云等: "RNA干扰技术在高脂血症实验动物基因治疗中的研究进展", 《中国心血管杂志》, vol. 19, no. 3, 25 June 2014 (2014-06-25), pages 234 - 236 *

Also Published As

Publication number Publication date
CA3143404C (en) 2024-03-05
GB202010004D0 (en) 2020-08-12
JP7463410B2 (ja) 2024-04-08
US20230027604A1 (en) 2023-01-26
WO2021001646A3 (en) 2021-02-18
EP3965781A2 (en) 2022-03-16
GB2585278A (en) 2021-01-06
CA3143404A1 (en) 2021-01-07
GB2585278B (en) 2022-03-16
JP2022537987A (ja) 2022-08-31
WO2021001646A2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CN114072503A (zh) 载脂蛋白b拮抗剂
EP3046627B1 (en) Modulation of efferocytosis pathways for treatment of atherosclerotic disease
JP2023519140A (ja) Ｐｃｓｋ９のアンタゴニスト
US11753639B2 (en) Micro-RNA and obesity
US20250304966A1 (en) Treatment of cardiovascular disease
EP3615694B1 (en) Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis
US20240352463A1 (en) Conjugate
JP7770924B2 (ja) Ｒａｓ変異体癌を治療するための組成物および方法
US20220259673A1 (en) Methods for identifying and treating high-plasticity cell state driving tumor progression in lung cancer
JPWO2021185765A5 (https=)
Tsujinaka et al. Angiogenesis inhibitor-specific hypertension increases the risk of developing aortic dissection
JP2007509604A (ja) 薬剤誘発下痢の予測のためのバイオマーカー
JP7527001B2 (ja) 疼痛の予防及び／又は治療用医薬組成物、並びに、疼痛抑制物質のスクリーニング方法
EP2483424B1 (en) Method for the diagnosis/prognosis of age-related macular degeneration
WO2025199495A1 (en) Compositions and methods for treatment and prevention of alzheimer's disease
EP3862438A1 (en) Acute renal failure-specific biomarker, acute renal failure diagnosis method, acute renal failure test kit, animal treatment method and acute renal failure medication
JP2023141905A (ja) 炎症性腸疾患の予防又は治療剤
JP2024508824A (ja) ミトコンドリアグリセロール－３－リン酸アシルトランスフェラーゼ（ｇｐａｍ）阻害剤による肝疾患の治療

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220218

WD01 Invention patent application deemed withdrawn after publication